Karthik Nath has a total of 171 co-authors. Here are the top co-authors by number of shared publications:

  • Georgina Hodges

    Department of Haematology and Bone Marrow Transplantation The Townsville Hospital Townsville Queensland Australia

    3 shared publications
  • Ian Irving

    Icon Cancer Centre Wesley Brisbane Queensland Australia

    3 shared publications
  • Maher K. Gandhi

    Mater Research, University of Queensland and Translational Research Institute

    3 shared publications
  • Michael Scordo

    Cellular Therapy Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York; Adult Bone Marrow Transplant Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York; Department of Medicine, Weill Cornell Medical College, New York, New York

    3 shared publications
  • Miguel-Angel Perales

    Memorial Sloan Kettering Cancer Center, New York, New York, United States

    3 shared publications
  • Ana Alarcon Tomas

    Division of Hematology and Hemotherapy, Hospital General Universitario Gregorio Marañón, Madrid, Spain

    2 shared publications

Latest Publications

  • Open Access

    Intra‐tumoral and peripheral blood TIGIT and PD‐1 as immune biomarkers in nodular lymphocyte predominant Hodgkin lymphoma

    by Jay Gunawardana, Soi C. Law, Muhammed B. Sabdia, Éanna Fennell, Aoife Hennessy, Ciara I. Leahy, Paul G. Murray, Karolina Bednarska, Sandra Brosda, Judith Trotman, et al.

    In classical Hodgkin lymphoma (cHL), responsiveness to immune‐checkpoint blockade (ICB) is associated with specific tumor microenvironment (TME) and peripheral blood features. The role of ICB in nodular lymphocyte predominant Hodgkin lymphoma (NLPHL) is not established. To gain insights into its potential in NLPHL, we compared TME and peripheral blood signatures between HLs using an integrative multiomic analysis. A discovery/validation approach in 121 NLPHL and 114 cHL patients highlighted >2‐fold enrichment in programmed cell death‐1 (PD‐1) and T‐cell Ig and ITIM domain (TIGIT) gene expression for NLPHL versus cHL. Multiplex imaging showed marked increase in intra‐tumoral protein expression of PD‐1+ (and/or TIGIT+) CD4+ T‐cells and PD‐1+CD8+ T‐cells in NLPHL compared to cHL. This included T‐cells that rosetted with lymphocyte predominant (LP) and Hodgkin Reed–Sternberg (HRS) cells. In NLPHL, intra‐tumoral PD‐1+CD4+ T‐cells frequently expressed TCF‐1, a marker of heightened T‐cell response to ICB. The peripheral blood signatures between HLs were also distinct, with higher levels of PD‐1+TIGIT+ in TH1, TH2, and regulatory CD4+ T‐cells in NLPHL versus cHL. Circulating PD‐1+CD4+ had high levels of TCF‐1. Notably, in both lymphomas, highly expanded populations of clonal TIGIT+PD‐1+CD4+ and TIGIT+PD‐1+CD8+ T‐cells in the blood were also present in the TME, indicating that immune‐checkpoint expressing T‐cells circulated between intra‐tumoral and blood compartments. In in vitro assays, ICB was capable of reducing rosette formation around LP and HRS cells, suggesting that disruption of rosetting may be a mechanism of action of ICB in HL. Overall, results indicate that further evaluation of ICB is warranted in NLPHL.


  • CAR T‐Cell Therapy for Multiple Myeloma: A Clinical Practice‐Oriented Review

    by Norah Layla Sadek, Bruno Almeida Costa, Karthik Nath, Sham Mailankody

    The emergence of chimeric antigen receptor (CAR) T‐cell therapy has revolutionized the treatment of hematologic malignancies, including multiple myeloma (MM). Two BCMA‐directed CAR T‐cell products — idecabtagene vicleucel (ide‐cel) and ciltacabtagene autoleucel (cilta‐cel) — have received US Food and Drug Administration (FDA) approval for patients with relapsed/refractory MM who underwent four or more prior lines of therapy (including an immunomodulatory agent, a proteasome inhibitor, and an anti‐CD38 monoclonal antibody). Despite producing unprecedented response rates in an otherwise difficult to treat patient population, CAR T‐cell therapies are commonly associated with immune‐related adverse events (e.g., cytokine release syndrome and neurotoxicity), cytopenias, and infections. Moreover, many patients continue to exhibit relapse post‐treatment, with resistance mechanisms yet to be fully understood. Ongoing basic, translational, and clinical research efforts are poised to generate deeper insights into the optimal utilization of these therapies, improve their efficacy, minimize associated toxicity, and identify new target antigens in patients with MM.


  • Open Access

    Reduced-Intensity Compared to Nonmyeloablative Conditioning in Patients with Non-Hodgkin Lymphoma Undergoing Allogeneic Hematopoietic Stem Cell Transplantation

    by Karthik Nath, Kristen Peterson, Samantha Brown, Sean Devlin, Natasia Rodriguez, Juliet Barker, Sergio Giralt, Boglarka Gyurkocza, Ann Jakubowski, Esperanza Papadopoulos, et al.


  • Prospective analysis to determine barriers to allogeneic hematopoietic cell transplantation in patients with acute leukemia

    by Karthik Nath, Jasme Lee, Theresa A. Elko, Lauren Levy, Elaina Preston, Sean M. Devlin, Doris M. Ponce, Richard J. Lin, Brian C. Shaffer, Christina Cho, et al.

    Allogeneic hematopoietic cell transplantation (allo-HCT) is a potentially curative treatment for patients with acute leukemia. Despite this, studies have shown that only a minority of patients ultimately proceed to allo-HCT. The primary objective of this prospective, observational study was to identify the rate of allo-HCT in patients for whom it was recommended, and reasons why patients deemed appropriate and eligible for HCT did not subsequently undergo transplant. Between April 2016 and April 2021, adult patients with newly diagnosed or relapsed/refractory acute leukemia were enrolled at the time of induction/reinduction therapy. Initial transplantation workup and allo-HCT recommendations were made during the early phase of induction/reinduction. Of the 307 enrolled patients, allo-HCT was recommended to 85% (n = 259), of whom 66% (n = 170) underwent transplant. Donor sources comprised 54% human leukocyte antigen (HLA)-matched unrelated donors, 20% HLA-matched sibling donors and HLA-mismatched graft sources with 15% umbilical cord blood units, 8% HLA-mismatched unrelated donors, and 4% HLA-haploidentical donors. The most common reason for transplant disqualification in the 89 patients in whom it was initially recommended was persistent/relapsed disease (70%), followed by early patient death (10%). In this prospective study, we report a high allo-HCT rate, which may be due to early transplant referral and workup. The main allo-HCT barrier was disease control, followed by early patient death. With the increasing availability of HLA-mismatched graft sources, the lack of donor availability was not a transplant barrier. Further development of novel transplant strategies for patients not achieving remission and improvements in induction regimens could result in increased allo-HCT utilization.


  • Safety evaluation of axicabtagene ciloleucel for relapsed or refractory large B-cell lymphoma

    by Karthik Nath, Kitsada Wudhikarn, Ana Alarcon Tomas, Miguel-Angel Perales

    : CD19-directed chimeric antigen receptor (CAR) T-cell therapy is a highly effective therapy for patients with relapsed/refractory large B-cell lymphoma (LBCL) and three CD19 CAR T-cell products (a...


  • A short course of daratumumab in patients with multiple myeloma and minimal residual disease after induction therapy

    by Karthik Nath, Tala Shekarkhand, Meghan Salcedo, Andriy Derkach, Siobhan Rueda, Aisara Chansakul, Malin Hulcrantz, Neha Korde, Urvi A. Shah, Carlyn Tan, et al.

    Despite the improved complete response (CR) rates in multiple myeloma with newer therapies, most patients still relapse [1]. In this regard, there has been development of more sensitive tools for r...

  • Activity and outcomes of autologous stem cell transplantation in the private sector in Australia

    by Karthik Nath, Yvette James, Debra Taylor, Raeina Gardner, Nicholas Rai, Robert S. Ware, Kerry Taylor, James Morton, Simon Durrant, Ian Irving, et al.

    Background: Few Australasian autologous stem cell transplantation (ASCT) programmes perform ASCT in the private sector. Relatively little is known about ASCT outcomes in the private sector, which varies in care delivery models to the public system.Aims: To investigate transplantation activity and survival outcomes at Icon Cancer Centre's Brisbane‐based private clinical and laboratory ASCT programme over a 23‐year period.Methods: Retrospective, observational study of all adults who underwent ASCT at Icon between 1996 and 2018. Main outcome measures were transplant activity, overall survival (OS) and 100‐day and 1‐year transplant‐related mortality (TRM). Outcomes were benchmarked against the Australasian Bone Marrow Transplant Recipient Registry (ABMTRR).Results: Between 1996 and 2018, 1676 ASCT were performed in 1454 patients. From 2010 to 2018, ASCT performed at Icon contributed 40% of all South East Queensland ASCT. In the past 5 years, 21% of Icon's patients were aged ≥70 years, compared with 5% across Australasia. For the entire cohort, 100‐day and 1‐year TRM was 1.1% and 1.7%, respectively, while for those aged ≥70 years, it was 2.0% and 3.1%. For ASCT performed between 2014 and 2018, 100‐day and 1‐year TRM was 0.8% and 1.4%, which was half the TRM rates reported by the ABMTRR. The 10‐year post‐transplant OS at Icon was higher than the ABMTRR data, across all disease subtypes.Conclusion: We report excellent OS and low TRM, demonstrating the critical role of the private sector in the administration of this highly complex therapy. The Icon ASCT programme is the largest ASCT contributor in Queensland. It is inclusive of patients aged ≥70 years, demonstrating low and acceptable TRM.


  • Open Access

    Vitamin D Insufficiency and Clinical Outcomes with Chimeric Antigen Receptor T-Cell Therapy in Large B-cell Lymphoma

    by Karthik Nath, Ana Alarcon Tomas, Jessica Flynn, Joshua A. Fein, Anna Alperovich, Theodora Anagnostou, Connie Lee Batlevi, Parastoo B. Dahi, Warren B. Fingrut, Sergio A. Giralt, et al.


  • Hepatitis B in haematology patients receiving intravenous immunoglobulin: highlighting a core issue

    by Karthik Nath, Thomas Wong, Ajit Ahluwalia, Scott Colquhoun, Paul J. Clark, Kerry Taylor, Sarah Cherian